ArticleERJ open research2025
Impact of seropositivity and disease-modifying antirheumatic drugs on pulmonary tuberculosis risk in rheumatoid arthritis.
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Inflammatory bowel disease and risk of non-tuberculous mycobacterial pulmonary disease: a nationwide retrospective cohort study in Korea.Journal of thoracic disease · 2026Article
- Risk of Stroke in COVID-19 Survivors With Asthma: A Nationwide, Population-Based Cohort Study.Journal of Korean medical science · 2025Article
- Screening and impact of comorbidities in bronchiectasis: a forward-looking perspective.Therapeutic advances in respiratory diseaseReview
- Incidence and risk factors for idiopathic pulmonary fibrosis in individuals aged 75 years and older in an ultra-aging society.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: It remains unclear whether active pulmonary tuberculosis risk is still high in rheumatoid arthritis patients in settings where tuberculosis infection screening is performed before the use of biologicals. Moreover, the impacts of seropositivity and disease-modifying antirheumatic drugs on active pulmonary tuberculosis risk should be elucidated. Methods: The incidence of active pulmonary tuberculosis was compared between patients with rheumatoid arthritis (n=59 577; 41 501 seropositive rheumatoid arthritis and 18 076 seronegative rheumatoid arthritis) and 1:5 age- and sex-matched controls without rheumatoid arthritis (n=297 885) enrolled between 2010 and 2017. The participants were followed until December 2019. Results: During a median follow-up duration of 4.4 years after a 1-year lag period (interquartile range 2.6-6.4 years; maximum 9 years), patients with rheumatoid arthritis showed a 3.2-fold (95% CI 2.91-3.55) higher active pulmonary tuberculosis risk than matched controls, even after adjusting for potential confounders. In an analysis of rheumatoid arthritis serological status, patients with seropositive rheumatoid arthritis and those with seronegative rheumatoid arthritis showed 3.20-fold (95% CI 2.86-3.58) and 2.54-fold (95% CI 2.13-3.04) increased risks, respectively, relative to matched controls. Furthermore, rheumatoid arthritis patients who were exposed to biological or targeted synthetic and disease-modifying antirheumatic drugs and those not exposed to the drugs showed 4.68-fold (95% CI 3.69-5.93) and 2.88-fold (95% CI 2.59-3.20) increased risks, respectively, relative to matched controls. In rheumatoid arthritis patients, active pulmonary tuberculosis risk factors included male sex, underweight and comorbidities such as diabetes mellitus. Conclusion: Rheumatoid arthritis patients are prone to active pulmonary tuberculosis development, with rates affected by seropositivity and disease-modifying antirheumatic drugs. Focused tuberculosis screenings may need to be carried out in rheumatoid arthritis patients based on our results.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.